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ABSTRACT
Epitope-based vaccines (EVs) have recently been
attracting significant interest. They trigger an
immune response by confronting the immune
system with immunogenic peptides derived from,
e.g. viral- or cancer-related proteins. Binding of
these peptides to proteins from the major histocom-
patibility complex (MHC) is crucial for immune
system activation. However, since the MHC is
highly polymorphic, different patients typically
bind different repertoires of peptides. Furthermore,
economical and regulatory issues impose strong
limitations on the number of peptides that can be
included in an EV. Hence, it is crucial to identify
the optimal set of peptides for a vaccine, given
constraints such as MHC allele probabilities in the
target population, peptide mutation rates and max-
imum number of selected peptides. OptiTope aims
at assisting immunologists in this critical task. With
OptiTope, we provide an easy-to-use tool to deter-
mine a provably optimal set of epitopes with respect
to overall immunogenicity in a specific individual
(personalized medicine) or a target population
(e.g. a certain ethnic group). OptiTope is available
at http://www.epitoolkit.org/optitope.
INTRODUCTION
Vaccines rank among the greatest achievements of modern
medicine. They utilize the adaptive part of the immune
system to prevent infections as well as to ﬁght chronic
diseases and cancer.
A vital event in the triggering of adaptive immunity
is the recognition of antigen-derived peptides bound to
major histocompatibility complex (MHC) class I and II
molecules by T-cell receptors. Since the MHC is highly
polymorphic, each individual possesses a set of MHC
class I and class II molecules of diﬀering speciﬁcities,
i.e. diﬀerent patients typically bind diﬀerent repertoires
of peptides. Peptides capable of causing an immune
response are called epitopes. These epitopes form the
basis of so-called epitope-based vaccines (EVs). A mixture
of well-chosen epitopes can evoke an immune response
precisely directed at conserved and highly immunogenic
regions of several antigens. Key criteria for selection are,
e.g. overall immunogenicity, tolerance for antigenic muta-
tions, population coverage and antigen coverage. Due to
the manifold advantages of EVs, discussed in detail in a
recent review (1), and their applicability in personalized
medicine, they have recently been attracting signiﬁcant
interest.
A crucial step in the design of an EV is the selection of
the epitopes: which set of epitopes yields the best immune
response in a given population or individual? Constraining
factors are economical and regulatory issues, which
impose strong limitations on the number of peptides
that can be included in an EV. This renders the epitope
selection an interesting optimization problem. Neverthe-
less, this critical task is typically performed manually. Sev-
eral computational approaches have been published (2–4).
In a recent paper (4), we proposed a mathematical frame-
work to ﬁnd a provably optimal set of epitopes for an EV.
Given a set of predicted or experimentally determined epi-
topes, the framework eﬃciently identiﬁes the set most
likely to elicit a broad and potent immune response in
the target population.
Based on a speciﬁc application of this framework,
OptiTope aims at assisting immunologists in the critical
task of epitope selection. It is an easy-to-use web-based
tool to eﬃciently determine an optimal set of epitopes in a
speciﬁc individual or a target population.
RELATED WEB SERVERS
Recently, two web-based tools aiding in vaccine design
have been published. Hotspot Hunter (5) identiﬁes immu-
nological hotspots on pathogenic proteins. The Mosaic
Vaccine Tool Suite (6) provides a set of web-based tools
for designing artiﬁcial recombinant proteins to be used
in T-cell vaccines. While the Mosaic Vaccine Tool Suite
focuses on a completely diﬀerent type of vaccine,
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MATERIALS AND METHODS
Mathematical Framework
OptiTope is based on a recently proposed mathematical
framework for the selection of an optimal set of peptides
for epitope-based vaccines (4). A brief outline of this
framework is given below.
The search for an optimal peptide set for an EV is inter-
preted as an optimization problem: out of a given set
of candidate epitopes, choose a subset which, out of all
subsets meeting certain requirements for a good vaccine
(e.g. mutation tolerance, population coverage), displays
maximum overall immunogenicity. Overall immunogeni-
city is deﬁned to be the immunity induced in the target
population and the following mathematical abstraction is
proposed: given a set of epitopes and a set of MHC alleles,
i.e. a target population, the overall immunogenicity of the
epitope set is assumed to be comprised of the immuno-
genicities of its components with respect to the diﬀerent
MHC alleles. Furthermore, the probability of an MHC
allele to occur within the target population directly aﬀects
the allele’s contribution to the overall immunogenicity.
(In this context, probability is commonly referred to as
frequency.) A common allele weighs more than an uncom-
mon allele. This yields a mathematical interpretation of
overall immunogenicity as weighted sum over immuno-
genicities of epitopes. Formulation of this optimization
problem as an integer linear program (7) allows ﬁnding
the optimal peptide set quite eﬃciently.
The underlying assumption of independence and addi-
tivity of immunogenicities of individual epitopes is, of
course, a simpliﬁcation. However, lacking a more sophis-
ticated model of the interplay of multiple epitopes in the
induction of an immune response, this assumption repre-
sents the state-of-the-art. For a more detailed discussion
of this problem and its implications, we refer to (4).
Target population or individual
Given the mathematical background of OptiTope, a target
population or individual is suﬃciently described by a set
of MHC alleles and their respective probabilities. The
NCBI dbMHC database (http://www.ncbi.nlm.nih.gov/
gv/mhc) contains data on MHC allele probabilities in var-
ious human populations and geographic areas (8). These
data were retrieved and made available to the OptiTope
users in order to facilitate the input of a target population.
Epitope immunogenicity
In order to increase the usability, OptiTope needs to
incorporate a method to predict immunogenicity.
Unfortunately, the prediction of immunogenicity is a
rather challenging problem and to our knowledge no suf-
ﬁciently accurate solution exists. However, in (9), Sette
et al. have demonstrated a correlation between immuno-
genicity and MHC class I binding aﬃnity. It is therefore
reasonable [and also very common (e.g. 3,10)] to use MHC
class I binding aﬃnity prediction methods for the predic-
tion of immunogenicity. OptiTope employs three widely
used MHC class I binding aﬃnity prediction methods,
namely BIMAS (11), SYFPEITHI (12) and SVMHC
(13). Prediction methods for MHC class II will be included
in the near future. Predictions of methods that are not
included in OptiTope, e.g. NetMHCpan (14) for MHC
class I or ProPred (15) for MHC class II, can be utilized
via the third input type: a table of epitopes and their
immunogenicities with respect to speciﬁc MHC alleles.
Since a positive prediction score does not necessarily
imply immunogenicity, a threshold is required to separate
non-immunogenic from immunogenic epitopes. OptiTope
oﬀers three kinds of thresholds: user-deﬁned, percentage
(16) and halfmax (16). The percentage thresholds are
calculated based on a large set of naturally occurring
peptides. Using, e.g. the 1% threshold, 1% of these pep-
tides would be classiﬁed as immunogenic. The halfmax
threshold corresponds to half of the maximal possible pre-
diction score.
Implementation
OptiTope is incorporated into the website SBS
EpiToolKit (16), which is based on the Zope application
server (http://www.zope.org), and the content manage-
ment system Plone (http://plone.org). For the user inter-
face, we employ dynamic HTML with CSS and
JavaScript. Python scripts are used for data validation
and processing. OptiTope was thoroughly tested for
compatibility with the popular web browsers Mozilla
Firefox (version 3.0.5) and Microsoft Internet Explorer
(version 7).
OptiTope uses the GNU Linear Programming Kit
GLPK (version 4.32, http://www.gnu.org/software/glpk)
and the GNU MathProg modeling language GMPL to
formulate and solve the optimization problems.
WEB INTERFACE
OptiTope requires the following input data: (i) sequences
of known antigens, (ii) a target population, i.e. MHC
alleles and corresponding probabilities and (iii) the user’s
requirements on the epitope set to be selected. The infor-
mation given by the user is transformed into an optimiza-
tion problem. If this problem is feasible, OptiTope will
return an optimal set of epitopes along with additional
information on their respective contribution to the overall
immunogenicity. Otherwise, OptiTope will propose
changes to the user’s requirements that might yield a fea-
sible optimization problem. The structure of the web inter-
face is depicted in Figure 1.
An introductory tutorial is provided on the OptiTope
home page to assist new users in learning how to use the
web server.
Conceptual design
For ease of use, the web interface is divided into four
steps: three input steps and one output step. Step-by-
step, the user is asked to enter the required data.
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navigation bar at the top of each site. The navigation
bar indicates the current step and contains corresponding
instructions. Furthermore, it provides access to a more
detailed help page. In order to keep the page layout
clear, settings and options are hidden from the user by
default. They can be accessed via the advanced options
button underneath the navigation bar.
Target sequences
In the ﬁrst step, the sequences of known target-speciﬁc
antigens are entered. They can either be pasted directly
or uploaded as a ﬁle. Three diﬀerent formats are accepted:
(i) a list of multiple sequence alignments (MSAs) in
FASTA format, (ii) a list of epitopes of equal length,
one epitope per line and (iii) a table of epitopes and
their (experimentally determined) immunogenicities with
respect to speciﬁc MHC alleles. Higher immunogenicity
values ought to indicate stronger immunogenicities.
Antigenic sequences entered as MSAs will be converted
into consensus sequences. From these sequences, all pep-
tides of a given length will be derived and will be consid-
ered as candidate epitopes. The user can adjust the peptide
length to be applied via the advanced options.
Target population
In the second step, information on the target population
has to be entered. This step is subdivided into two queries.
The user is queried for (i) the MHC alleles to consider
(if they have not already been entered in the previous
step) and (ii) for their probabilities in the target
population.
(i) MHC alleles can be selected by population or geo-
graphic area based on data (8) retrieved from the
NCBI dbMHC database (http://www.ncbi.nlm.nih.
gov/gv/mhc). The corresponding probabilities will
be employed for the next query. Alternatively, the
MHC alleles can be selected manually from an
expandable allele tree (16) or by pasting a list of
alleles.
(ii) In this step, a list of the selected MHC alleles along
with probabilities (default values or values retrieved
from the NCBI dbMHC database, respectively)
is given. These probabilities can either be modiﬁed
manually or they can be replaced by population or
geographic area-speciﬁc probabilities from the
NCBI dbMHC database via the advanced options.
Individual MHC alleles can be excluded from fur-
ther processing. Furthermore, low probability MHC
Figure 1. Structure of the OptiTope web interface. OptiTope is divided into four parts: target antigens, target population, constraints and results.
(i) Target antigens: three diﬀerent formats of antigenic sequences can be entered: (a) a list of multiple sequence alignments of target-speciﬁc antigens,
(b) a list of epitopes and (c) a table of epitopes with (experimentally determined) immunogenicities with respect to speciﬁc alleles. (ii) Target
population: the information required to specify the target population (MHC alleles and corresponding probabilities) depends on the chosen input
format. (iii) Constraints: OptiTope oﬀers a set of constraints, which can be modiﬁed or excluded by the user. (iv) Results: if feasible, OptiTope
presents an optimal set of epitopes.
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process via a ﬁlter in the advanced options section.
If the user has not entered the immunogenicities of the
candidate epitopes together with the target sequences,
OptiTope will employ a prediction method to determine
the respective immunogenicities. The prediction method to
be employed can be selected via the advanced options.
Constraints
In the third step, the user is queried for the requirements
on the epitope set to be selected. Depending on the data
that have been entered in the previous steps (a summary
of these data is given), a list of suitable constraints is
displayed. The user can (de)select and modify these
constraints. Potential constraints are:
 Maximum number of epitopes to select. This con-
straint deﬁnes the maximum number of epitopes
OptiTope should select. It is the only obligatory
constraint.
 Minimum epitope conservation. This constraint
ensures that only epitopes that fulﬁll a user-deﬁned
conservation requirement will be considered.
 Minimum number of alleles to cover. An MHC allele
is considered to be covered by an epitope set, if one of
the epitopes is suﬃciently immunogenic with respect
to the allele. If this constraint is selected, the optimal
set of epitopes will be immunogenic with respect to the
speciﬁed number of alleles or more.
 Minimum number of antigens to cover. An antigen is
considered to be covered by an epitope set, if one
of the epitopes is derived from this antigen. This con-
straint guarantees that the optimal epitope set will
include epitopes from a speciﬁed number of antigens
or more.
The advanced options oﬀer the possibility to set an
immunogenicity threshold, i.e. a minimum immunogeni-
city score required for a peptide to be considered immu-
nogenic with respect to a speciﬁc allele. Only peptides
which score above this threshold for at least one MHC
allele will be considered during epitope selection.
Results
The results page gives a summary of the input data and
the selected constraints as well as the results of the
optimization.
If the optimization problem is feasible, a
table containing the optimal set of epitopes will be dis-
played (Figure 2). For every epitope in the set the follow-
ing information is given: its fraction of the overall
immunogenicity, a list of the MHC alleles it covers and,
if antigen information was given, the corresponding
Figure 2. A screenshot from the results page of OptiTope.
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table, which contains additional information on epitope
conservation and immunogenicities. Information on the
size of the selected set, the number of covered alleles and
on the number of covered antigens, if applicable, is dis-
played above the table. Furthermore, the coverage of each
of the given MHC loci and the corresponding population
coverage are given. (If locus A has a coverage of 75%, the
probability of an individual from the target population
carrying a covered allele at locus A is 75%. A population
coverage of 80% corresponds to a probability of 80% for
an individual from the target population to carry at least
one of the covered alleles.) The results can be downloaded.
A choice of two ﬁle formats is given: XLS (MS Excel) and
CSV (comma separated values). For typical problem sizes,
OptiTope ﬁnds an optimal set of peptides within seconds.
Nevertheless, the user can choose to be notiﬁed of the
completion of the request via e-mail.
If the optimization problem is infeasible, meaning that
no set of epitopes from the given antigenic sequences
fulﬁlls all requirements, a basic analysis of the problem
is performed. Based on this analysis, OptiTope suggests
constraint modiﬁcations that might result in a feasible
problem. If the basic analysis does not yield a possible
explanation for the infeasibility, OptiTope will suggest
to deselect individual constraints or to increase the
number of epitopes to be selected.
CASE STUDY
In order to demonstrate the performance of OptiTope, we
used it to select epitopes suitable for a hepatitis C virus
(HCV) vaccine for the European population. An HCV
dataset from (4) was utilized as antigenic sequence input.
It consists of 10 MSAs corresponding to 10 diﬀerent HCV
proteins from four diﬀerent strains, totaling in 4054 anti-
genic sequences. (This dataset is provided as an example
dataset on the web server.) Default settings were used,
i.e. immunogenicity prediction using BIMAS, a minimum
conservation of 20%, coverage of at least 5 out of
10 antigens and of at least 10 out of 19 alleles. Within a
few seconds, OptiTope returns a set of 10 epitopes cover-
ing 5 antigens and 10 alleles, yielding a locus coverage of
54% for locus A, 20% for locus B and 35% for locus
C. The corresponding population coverage is 94.28%.
Three of these epitopes are known HCV epitopes and
can be found in the Immune Epitope Database (IEDB,
release 2008_4_1_3_28) (17). Another three epitopes are
contained in known longer epitopes. Increasing allele cov-
erage to 19, i.e. 100%, increases locus coverage for locus A
to 79% and to 56% for locus B. Population coverage
is increased to 99.63% (Figure 2). The selected set of epi-
topes includes ﬁve known HCV epitopes and another two
epitopes contained in known longer epitopes. Again, this
set of epitopes is found within a few seconds.
CONCLUSION
With OptiTope, we provide an easy-to-use tool that
assists immunologists in designing EVs. Given a set of
antigenic sequences of interest, a target population and
special requirements of the user, OptiTope eﬃciently
determines an optimal set of epitopes. To our knowledge,
OptiTope is the ﬁrst web-based approach for optimal
vaccine design.
Currently, OptiTope only oﬀers immunogenicity predic-
tions for MHC class I, i.e. the only way to include MHC
class II in the selection process is via the third input type:
a table of epitopes and their immunogenicities with respect
to speciﬁc MHC alleles. We plan to add MHC class II
predictions and further MHC class I prediction methods
in the future. A reﬁnement of the analysis of infeasible
problems in order to provide the user with more detailed
information is also intended. Furthermore, we will
enhance the results page by linking selected epitopes that
can be found in the IEDB (17) to the corresponding IEDB
site.
Due to the lack of a more sophisticated model of immu-
nogenicity, OptiTope is forced to employ a commonly
used additive model as well as prediction methods for
MHC binding instead of immunogenicity. However, this
does not pose fundamental limitations to the method.
ACKNOWLEDGEMENTS
The authors wish to thank Sebastian Briesemeister and
Magdalena Feldhahn for valuable comments on the
design of this web site.
FUNDING
Deutsche Forschungsgemeinschaft (SFB 685/B1).
Funding to open access charge: Deutsche Forschungsge-
meinschaft (SFB 685/B1).
Conﬂict of interest statement. None declared.
REFERENCES
1. Purcell,A.W., McCluskey,J. and Rossjohn,J. (2007) More than one
reason to rethink the use of peptides in vaccine design. Nat. Rev.
Drug Discov., 6, 404–414.
2. Groot,A.S.D., Marcon,L., Bishop,E.A., Rivera,D., Kutzler,M.,
Weiner,D.B. and Martin,W. (2005) HIV vaccine development by
computer assisted design: the GAIA vaccine. Vaccine, 23,
2136–2148.
3. Vider-Shalit,T., Raﬀaeli,S. and Louzoun,Y. (2007) Virus-epitope
vaccine design: informatic matching the HLA-I polymorphism to
the virus genome. Mol. Immunol., 44, 1253–1261.
4. Toussaint,N.C., Do ¨ nnes,P. and Kohlbacher,O. (2008) A mathema-
tical framework for the selection of an optimal set of peptides for
epitope-based vaccines. PLoS Comput. Biol., 4, e1000246.
5. Zhang,G.L., Khan,A.M., Kellathur,N.S., Heiny,A.T., Lee,K.X.,
Kwoh,C.K., August,J.T. and Brusic,V. (2008) Hotspot Hunter: a
computational system for large-scale screening and selection of
candidate immunological hotspots in pathogen proteomes. BMC
Bioinformatics, 9 (Suppl. 1), S19.
6. Thurmond,J., Yoon,H., Kuiken,C., Yusim,K., Perkins,S., Theiler,J.,
Bhattacharya,T., Korber,B. and Fischer,W. (2008) Web-based
design and evaluation of T-cell vaccine candidates. Bioinformatics,
24, 1639–1640.
7. Schrijver,A. (1986) Theory Of Linear And Integer Linear
Programming., John Wiley & Sons, New York.
8. Meyer,D., Singe,R.M., Mack,S.J., Lancaster,A., Nelson,M.P.,
Erlich,H., Fernandez-Vina,M. and Thomson,G. (2007) Single locus
Nucleic AcidsResearch, 2009, Vol.37, WebServer issue W621polymorphism of classical HLA genes. In Hansen,J.A. (ed.),
Immunobiology of the Human MHC: Proceedings of the 13th
International Histocompatibility Workshop and Conference, Vol. I,
IHWG Press, Seattle, WA, pp. 653–704.
9. Sette,A., Vitiello,A., Reherman,B., Fowler,P., Nayersina,R.,
Kast,W.M., Melief,C.J., Oseroﬀ,C., Yuan,L., Ruppert,J. et al.
(1994) The relationship between class I binding aﬃnity and immu-
nogenicity of potential cytotoxic T cell epitopes. J. Immunol., 153,
5586–5592.
10. Groot,A.S.D. and Moise,L. (2007) Prediction of immunogenicity
for therapeutic proteins: state of the art. Curr. Opin. Drug Discov.
Devel., 10, 332–340.
11. Parker,K.C., Bednarek,M.A. and Coligan,J.E. (1994)
Scheme for ranking potential HLA-A2 binding peptides based on
independent binding of individual peptide side-chains. J. Immunol.,
152, 163–175.
12. Rammensee,H., Bachmann,J., Emmerich,N.P., Bachor,O.A. and
Stevanovic,S. (1999) SYFPEITHI: database for MHC ligands and
peptide motifs. Immunogenetics, 50, 213–219.
13. Do ¨ nnes,P. and Kohlbacher,O. (2006) SVMHC: a server for
prediction of MHC-binding peptides. Nucleic Acids Res., 34,
W194–W197.
14. Nielsen,M., Lundegaard,C., Blicher,T., Lamberth,K., Harndahl,M.,
Justesen,S., Røder,G., Peters,B., Sette,A., Lund,O. et al. (2007)
NetMHCpan, a method for quantitative predictions of peptide
binding to any HLA-A and –B locus protein of known sequence.
PLoS ONE, 2, e796.
15. Singh,H. and Raghava,G.P. (2001) ProPred: prediction of HLA-DR
binding sites. Bioinformatics, 17, 1236–1237.
16. Feldhahn,M., Thiel,P., Schuler,M.M., Hillen,N., Stevanovic,S.,
Rammensee,H.G. and Kohlbacher,O. (2008) EpiToolKit – a web
server for computational immunomics. Nucleic Acids Res., 36,
W519–W522.
17. Peters,B., Sidney,J., Bourne,P., Bui,H.H., Buus,S., Doh,G.,
Fleri,W., Kronenberg,M., Kubo,R., Lund,O. et al. (2005) The
immune epitope database and analysis resource: from vision to
blueprint. PLoS Biol., 3, e91.
W622 Nucleic Acids Research, 2009, Vol. 37,WebServer issue